Home > Pulmonology > ERS 2019 > Interstitial Lung Disease > Registry Confirms Nintedanib Efficacy under Real-life Conditions

Registry Confirms Nintedanib Efficacy under Real-life Conditions

Presented By
Prof. Jürgen Behr, Ludwig-Maximilian-University Munich, Germany
Conference
ERS 2019
Trial
INSIGHTS-IPF

Data from the German INSIGHTS-IPF registry have shown that therapy with nintedanib reduces mortality in idiopathic pulmonary fibrosis (IPF) patients by 37% compared with placebo [1].

Registries are an important tool to assess the efficacy and safety of drugs in a real-world scenario. To assess the effects of nintedanib under real-life conditions, Prof. Jürgen Behr (Ludwig-Maximilian-University Munich, Germany) and his colleagues analysed data from a non-interventional, prospective cohort study of consecutively enrolled IPF patients in 20 interstitial lung disease (ILD) expert centres in Germany, the INSIGHTS-IPF registry.

Data of 588 IPF patients with a disease duration of 1.8 ± 3.4 years were included in the analysis. Propensity scores were applied to account for known differences in baseline characteristics of patients.

During a mean follow-up of 1.2 ± 0.7 years, 33% of patients died. The 1-year and 2-year survival for patients with versus ...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on